Fractyl Health(GUTS.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Fractyl Health
GUTS.US
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc.
1.376 T
GUTS.USMarket value -Rank by Market Cap -/-

Financial Score

18/01/2026 Update
E
Health Care EquipmentIndustry
Industry Ranking172/176
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-518.40%E
    • Profit Margin-4073233.33%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-96.91%E
    • Net Profit YoY-77.17%E
    • Total Assets YoY-9.97%E
    • Net Assets YoY-106.32%E
  • Cash ScoreD
    • Cash Flow Margin0.00%D
    • OCF YoY-96.91%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreE
    • Gearing Ratio102.78%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fractyl Health Inc. Files Initial Beneficial Ownership Statement for CFO Lara Smith Weber

    Fractyl Health Inc. has filed an initial beneficial ownership statement (Form 3) with the U.S. SEC, listing Lara Weber Smith as the beneficial owner in her role as CFO. The full filing is accessible via the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    GUTS
    -3.05%
    Reuters·
    US
    GUTS
    -3.05%

    Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer

    Fractyl Health Inc. has appointed Lara Smith Weber as Chief Financial Officer, effective January 12, 2026. She will oversee finance, accounting, and investor relations, succeeding Lisa Davidson, who will step down on December 31, 2025, and assist during the transition.

    Reuters·
    US
    GUTS
    -3.05%
    Reuters·
    US
    GUTS
    -3.05%

    Fractyl Health: Advancing Revita and Rejuva Pipelines Toward 2026 Clinical and Regulatory Catalysts Supports Buy Rating

    Analyst Joseph Pantginis of H.C. Wainwright has maintained a Buy rating on Fractyl Health, Inc. with a price target of $8.00. He cites the company's advancing clinical pipeline, particularly the Revita therapy, which shows promising results in weight maintenance and metabolic control. Upcoming data sets and regulatory milestones in 2026 are expected to enhance the company's value. Additionally, the Rejuva pancreatic gene therapy platform is highlighted for its potential in treating type 2 diabetes and obesity, further supporting the Buy recommendation.

    Tip Ranks·
    US
    GUTS
    -3.05%
    Tip Ranks·
    US
    GUTS
    -3.05%

    Fractyl Health Raises $23 Million from Tranche A Warrant Exercises

    Fractyl Health Inc. has raised $23 million from the exercise of Tranche A warrants linked to its August 2025 financing. An additional $4.1 million was received on January 2, 2026, increasing the company's cash and cash equivalents to approximately $85.6 million. The funds will support Fractyl's clinical and regulatory milestones through early 2027.

    Reuters·
    US
    GUTS
    -3.05%
    Reuters·
    US
    GUTS
    -3.05%

    Analysts keep buy ratings on Fractyl Health (GUTS)

    Analysts at Canaccord Genuity have maintained a Buy rating on Fractyl Health, Inc. (NASDAQ:GUTS), setting a price target of $8. This decision follows a series of virtual meetings with the company's leadership, highlighting Fractyl Health as one of the top new penny stocks to invest in.

    MSN·
    US
    GUTS
    -3.05%
    MSN·
    US
    GUTS
    -3.05%
    © 2026 Longbridge｜Disclaimer